We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
GMR CAR-T cell therapy represents a promising strategy for CD116⁺ R/R AML.
No takes yet. Share an insight, caveat, or question.
Hasegawa et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: